Gender | Age
Item
female patients, ≥ 18 years of age.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
HER2-positive carcinoma of breast
Item
her2-positive breast cancer.
boolean
C1960398 (UMLS CUI [1])
Residual disease Absent | Recurrent disease Locally Absent | Neoplasm Metastasis Absent | Status post Operative Surgical Procedure Completion | Status post Neoadjuvant Chemotherapy Completion | Status post Adjuvant Chemotherapy Completion
Item
no evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neoadjuvant or adjuvant).
boolean
C0543478 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0277556 (UMLS CUI [2,1])
C1517927 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0027627 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0231290 (UMLS CUI [4,1])
C0543467 (UMLS CUI [4,2])
C0205197 (UMLS CUI [4,3])
C0231290 (UMLS CUI [5,1])
C0600558 (UMLS CUI [5,2])
C3665472 (UMLS CUI [5,3])
C0205197 (UMLS CUI [5,4])
C0231290 (UMLS CUI [6,1])
C0085533 (UMLS CUI [6,2])
C0205197 (UMLS CUI [6,3])
Adjuvant Chemotherapy Completed | Radiotherapy, Adjuvant
Item
all adjuvant chemotherapy must be completed; adjuvant radiotherapy may be ongoing.
boolean
C0085533 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0242939 (UMLS CUI [2])
Herceptin Intravenous Pre-existing | Requirement Course Quantity
Item
patients who have already received intravenous herceptin must have at least 8 out of the total planned 18 3-week cycles remaining.
boolean
C0338204 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
C2347662 (UMLS CUI [1,3])
C1514873 (UMLS CUI [2,1])
C0750729 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Cancer Other | Exception DCIS | Exception Curative treatment Carcinoma in situ of uterine cervix | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Cancer Other | Exception Disease Free Duration
Item
history of other malignancy, except for ductal carcinoma in situ of the breast, curatively treated carcinoma in situ of the cervix or basal cell carcinoma, or other curatively treated malignancies that have been disease-free for at least 5 years.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007124 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0851140 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0007117 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C1273390 (UMLS CUI [5,2])
C1707251 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
C0332296 (UMLS CUI [6,3])
C0449238 (UMLS CUI [6,4])
Bone Marrow function Inadequate
Item
inadequate bone marrow function.
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
Liver Dysfunction
Item
impaired liver function.
boolean
C0086565 (UMLS CUI [1])
Renal function Inadequate
Item
inadequate renal function.
boolean
C0232804 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
Cardiovascular Disease Serious
Item
serious cardiovascular disease.
boolean
C0007222 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
HIV Infection | Hepatitis B | Hepatitis C
Item
human immunodeficiency virus (hiv) or hepatitis b (hbv) or c (hcv) infection.
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Doxorubicin Cumulative Dose Maximum | Epirubicin Cumulative Dose Maximum | Doxorubicin Dose Equivalent | Epirubicin Dose Equivalent
Item
prior maximum cumulative dose of doxorubicin > 360 mg/m^2 or epirubicin > 720 mg/m^2 or equivalent.
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C0014582 (UMLS CUI [2,1])
C2986497 (UMLS CUI [2,2])
C0806909 (UMLS CUI [2,3])
C0013089 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205163 (UMLS CUI [3,3])
C0014582 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205163 (UMLS CUI [4,3])